Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease

AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease

Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology

Warren Remedies commences commercial production of APIs

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes

Briefs: Concord Biotech and Neuland Laboratories

The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483

Sharon Bio-Medicine resumes operations

Operations of Line II was stopped due to a fire incident earlier

USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

Oscotec has successfully completed phase 2 study in patients with chronic ITP last year

Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India

Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI

Zydus receives tentative approval from USFDA for Letermovir Tablets

Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)